Systematic Review and Network Meta-Analysis of First-Line Therapies for Cervical Cancer

A 2026 systematic review and network meta-analysis by Xiaoge Wang, aggregating data from four Phase III randomized controlled trials involving 1,924 patients. The study compares the efficacy and safety of first-line immunotherapy regimens for persistent, recurrent, or metastatic cervical cancer, analyzing endpoints like overall survival and progression-free survival.

Use Cases

• Comparing the efficacy of pembrolizumab, atezolizumab, and cadonilimab regimens based on reported hazard ratios for overall and progression-free survival.
• Analyzing treatment outcomes for PD-L1 positive versus negative patient subgroups based on combined positive score thresholds mentioned in the results.
• Evaluating the safety profile of different immunotherapy combinations based on the incidence of grade ≥3 treatment-related adverse events.
• Informing clinical decision-making by integrating findings on PD-L1 expression status and bevacizumab eligibility discussed in the conclusion.

Strengths

• Analysis is based on four Phase III randomized controlled trials, a gold standard study design.
• Includes data from 1,924 patients, providing a substantial sample for meta-analysis.
• Registered with PROSPERO (CRD420251158152), indicating adherence to systematic review protocols.
• Uses network meta-analysis and Bucher's indirect comparison method for statistical rigor.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The primary data file is a DOCX document, which may require extraction and structuring for computational analysis.

Provenance

Source

figshare, author Xiaoge Wang.

Collection Method

Systematic review of PubMed, Embase, and Web of Science databases for Phase III RCTs.

Time Range

Temporal coverage of the included clinical trials is not specified.

Freshness

Last updated 2026-04-16 05:25:34; freshness should be verified.

Geography

Spatial coverage of the patient populations is not specified.